Sophia Genetics enables institutions around the world to launch world-class oncology tests
Boston, Massachusetts And the roll, Switzerland, February 24, 2025 /PRNewswire/ -Sophia Genetics (NASDAQ: SOPH), a pioneer of AI Healthcare Technology and data-driven medicine, is a new miles to global adoption of a groundbreaking cancer testing application powered by Sophia DDM. Stone has been announced. Equipped with ™ and MSK-IMPACT® SophiaDDM™. Thirty-seven prominent institutions, including top researchers and leading opinion leaders around the world, have already adopted recently launched liquid biopsy and solid tumor applications.
Professor Umberto MalapelleChair of the Institute of Predictive Molecular Pathology, Department of Public Health, University of Federico II. Naples, Italy The International Association of Liquid Biopsys Sciences has defended a new application to support his research on lungs and other cancers.
“When we learn that Sophia Genetics is offering applications from MSK on the Sophia DDM™ platform, we see Sophia Genetics as a real collaborator, particularly to help pave the way for the future. So I was really interested in assessing the performance of this test.'' in cancer research, said Professor Malapel.
“Bringing best-in-class technology to global organizations is critical to promoting better healthcare for all. We work with pioneers like Professor Malapel to help us with the aim of working with us. The next wave of cancer treatments has been said to be the next wave of cancer treatments. Ross Mukenpresident, Sophia Genetics.
Of the 37 institutions employing MSK solutions, only 10 months after the launch of their liquid biopsy application, 31 institutions employing MSK-Access® with Sophia DDM™ have been signed. Decentralization The deployment of MSK-ACCESS® allows hospitals and labs around the world to launch world-renowned liquid biopsy tests from the walls of their facilities, providing patients with a less invasive option for genomic testing I did. Often this Decentralization Testing also reduces costs and speeds turnaround times, but allows institutions to control patient data for research and other purposes.
The internationally recognized organizations employing the application are: Germany; Bioptica Research Institute Czech Republic;Hospital del Mar and Hospital La fe in SpainNice University Hospital and Marseille Regional Hospital Center Franceand Jewish General Hospital Canada.
A complementary solid tumor application powered by Sophia DDM™, MSK-IMPACT® is attracting great interest from leading organizations around the world. SpainCyprus Institute of Neurology and Genetics Cyprusand sofiva genomics Taiwan.
Memorial Sloan Kettering Cancer Center (MSK) and Sophia Genetics will deliver MSK's cutting-edge cancer testing capabilities to precision medical institutions around the world in 2023, using sophisticated technology from the Sophia DDM™ platform. We partnered with the vision of doing so. The two leaders have launched the liquid biopsy test msk-access® with sophia ddm™ April 2024. in October 2024Sophia Genetics has announced a decisive partnership agreement with Astrazeneca (LSE/STO/NASDAQ: AZN) to accelerate the deployment of MSK-Access® with Sophia DDM™, bringing this innovative liquid organism around the world It aims to increase the availability of solutions. in November 2024Sophia Genetics has announced the launch of MSK-Impact®, a complementary solid tumor test powered by Sophia DDM™. These collaborations can transform cancer research as healthcare providers can draw from the ever-evolving foundations of real-world data and gain insights from diverse populations using best-in-class technology. It has sex.
Please participate Tuesday, February 25th, 2025in 11am (11:00) EDT / 5pm (17:00) Precision Oncology Showcase CET, Virtual Webinar to spotlight the possibilities of conversion DecentralizationAI-driven technology for advances in cancer treatment.
About Sofia Genetics
Sophia Genetics (NASDAQ: SOPH) is a cloud-native healthcare technology company on its mission to transform patient care by expanding access to data-driven healthcare globally. It is the creator of the Sophia DDM™ platform, analyzing complex genomic and multimodal data and generating real-time practical insights for a wide global network of hospitals, labs, and biopharma institutions. For more information, go to sophiagenetics.com and connect via LinkedIn.
Sophia Genetics products are intended for research purposes only, not for use in diagnostic procedures unless otherwise specified. The information in this press release is about products that may be available in different countries and, where applicable, receive approval or market clearance from government regulatory bodies for various adaptations for use. It may or may not have been received. Please contact us (Email protection) To get the appropriate product information for your country of residence.
memorial Sloan Kettering (MSK) There are institutional economic benefits associated with Sophia Genetics.
Forward-looking statements
This press release contains statements that constitute forward-looking statements. All statements other than the historical fact statements contained in this press release include the planning and purpose of Sophia Genetics' future operations and financial position, business strategy, products and technologies, partnerships and collaboration, and management of future operations. All statements contained in this press release, including statements relating to the following: Forward-looking statements are based on the beliefs and assumptions of Sophia Genetics management teams and information currently available to the company managers. Such statements are subject to risk and uncertainty, and actual results are subject to forward-looking statements due to a variety of factors, including factors stated in the company's filings with the U.S. Securities and Exchange Commission. The results may differ materially from the expressed or implied results. We cannot guarantee that such future results will be achieved. Such forward-looking statements contained in this press release are made available only as of that date. We expressly disclaim any obligation or effort to update these forward-looking statements contained in this press release. Applicable law. No representation or warranty (representation or implied) is made regarding the accuracy of such forward-looking statements.
Source Sophia Genetics
